Neuroscience
A brief overview to some of the anticipated insomnia medications trending from this year to next, this is from a recent Reuters report, as published on the International Herald Tribune website:
-
Anthony H. Risser | neuroscience | neuropsychology | brain
- Business World: New Insomnia Meds, Including Takeda's Ramelteon (rozerem, Tak-375) (cont.)
Forbes.com offers a take on what's happening in the insomnia market: The Next Ambien? Matthew Herper Forbes.com 07.21.05, 6:00 AM ET Read the article. - Anthony H. Risser | neuroscience | neuropsychology | brain...
- Business World: Takeda's Ramelteon (tak-375)
A Reuters report:Takeda may extend sleeping pill's use for Alzheimer's Mon Jul 11, 2005 05:41 AM ET TOKYO, July 11 (Reuters) - Japan's biggest drug maker, Takeda Pharmaceutical Co. Ltd ... said on Monday it is on track to release a sleeping...
- Lunesta (eszopiclone)
With New Sleeping Pill, New Acceptability? By ANDREW POLLACK The New York Times 17 December 2004 Is it a wake-up call for the sleeping pill market? With Wednesday's approval of Sepracor's new drug, Lunesta, a taboo in the use of sleeping...
- Business World: Emd 281014 And Insomnia
From the New York Times website: Lilly to Buy Insomnia Compound By THE ASSOCIATED PRESS Published: October 28, 2004 Filed at 11:21 a.m. ET INDIANAPOLIS (AP) -- Eli Lilly and Co. will pay a German pharmaceutical company $29 million for the...
- Forthcoming Meeting: Exanta And Stroke Prevention
Reuters reports that the FDA will be holding a meeting tomorrow to discuss Exanta and its use as an anti-stroke medication. Here is the text of the FDA announcement about this meeting: FDA Announcement and the text of the FDA Briefing Note: FDA Briefing...
Neuroscience
Business World: New Insomnia Meds, Including Takeda's Ramelteon (Rozerem, TAK-375)
A brief overview to some of the anticipated insomnia medications trending from this year to next, this is from a recent Reuters report, as published on the International Herald Tribune website:
New entries shake insomnia market's slumber[ ... Read the full report ... ]
Reuters
FRIDAY, JULY 15, 2005
LONDON The sleeping pill market, long dominated by Sanofi-Aventis's Ambien, is waking up to a rush of new competition.
Improved treatments could double the insomnia market by the end of the decade, but the French company's share of business is set to shrink dramatically, according to industry analysts.
The latest challenger is Takeda Pharmaceutical's Rozerem, or ramelteon, which industry sources say could win approval in the crucial U.S. market as early as next week. The expected approval comes hard on the heels of the successful U.S. debut of Sepracor's Lunesta in April.
Another two competitors - from two U.S. pharmaceutical companies, Pfizer and Merck - are expected in 2006 and 2008, respectively.
-
Anthony H. Risser | neuroscience | neuropsychology | brain
- Business World: New Insomnia Meds, Including Takeda's Ramelteon (rozerem, Tak-375) (cont.)
Forbes.com offers a take on what's happening in the insomnia market: The Next Ambien? Matthew Herper Forbes.com 07.21.05, 6:00 AM ET Read the article. - Anthony H. Risser | neuroscience | neuropsychology | brain...
- Business World: Takeda's Ramelteon (tak-375)
A Reuters report:Takeda may extend sleeping pill's use for Alzheimer's Mon Jul 11, 2005 05:41 AM ET TOKYO, July 11 (Reuters) - Japan's biggest drug maker, Takeda Pharmaceutical Co. Ltd ... said on Monday it is on track to release a sleeping...
- Lunesta (eszopiclone)
With New Sleeping Pill, New Acceptability? By ANDREW POLLACK The New York Times 17 December 2004 Is it a wake-up call for the sleeping pill market? With Wednesday's approval of Sepracor's new drug, Lunesta, a taboo in the use of sleeping...
- Business World: Emd 281014 And Insomnia
From the New York Times website: Lilly to Buy Insomnia Compound By THE ASSOCIATED PRESS Published: October 28, 2004 Filed at 11:21 a.m. ET INDIANAPOLIS (AP) -- Eli Lilly and Co. will pay a German pharmaceutical company $29 million for the...
- Forthcoming Meeting: Exanta And Stroke Prevention
Reuters reports that the FDA will be holding a meeting tomorrow to discuss Exanta and its use as an anti-stroke medication. Here is the text of the FDA announcement about this meeting: FDA Announcement and the text of the FDA Briefing Note: FDA Briefing...